Vision Optique
Blog Hero

Take Control of Your Child’s Myopia

Writings by @DrBridgitte

Myopia, more commonly known as nearsightedness, is rising among children. The eyes of a child with myopia become longer over time, causing distant objects to appear blurry. If not managed properly, myopia often worsens as the child gets older. High myopia affects the quality of life and can lead to serious eye-health complications later in life.

At Vision Optique, our experienced doctors follow the latest evidence-based myopia management treatments. Our doctors also conduct FDA clinical trials for future treatment options.

Following an initial consultation visit (virtual or in-person) with both parents and patient, our team will review the examination process, selection of treatment strategies, identified risks, and guidelines for ongoing management.

Our treatment options include:

Daytime MiSight® 1-Day Contact Lens

MiSight® 1 day is the first and only FDA-approved soft contact lens to slow the progression of myopia in children ages 8 -12 at the initiation of treatment.

Over a 3-year period, MiSight® 1 day slowed myopia progression by 59% on average and reduced eye lengthening by 52% on average.  41% of eyes had no progression. Over a 6-year period, children wearing MiSight® 1 day progressed less than 1.00 D on average.  Vision Optique is among the first certified MiSight® medical practices and has been prescribing MiSight® since early 2020.

Overnight Therapeutic Ortho-K Lenses

ACUVUE® Abiliti™ (Johnson & Johnson Vision) Overnight Therapeutic Lens is new, and it is the first and only FDA-approved orthokeratology contact lens for myopia management. Paragon CRT® and CRT Dual-Axis® (CooperVision Specialty EyeCare) Ortho-K lenses are FDA-approved for overnight wear. Paragon CRT® lenses are among the most commonly prescribed, and they have worked well for Vision Optique’s young patients. These therapeutic lenses are worn while children sleep, enabling them to enjoy clear and comfortable vision during the day without any glasses or contact lenses.

Overnight Low Dose Prescription Atropine Eye Drops

Topical low-dose atropine is an emerging therapy for myopia management. Several well-controlled clinical trials (e.g. LAMP phase 2, ATOM1, and ATOM2) have been published. They have worked well for Vision Optique’s young patients. Schedule an appointment with our doctors to discuss this treatment option for your child.

Daytime Spectacle Lenses

Our doctors are conducting a multi-year FDA clinical trial on this technology. Currently, there is no FDA-approved ophthalmic lens for myopia management in the United States.

More Outdoor Time

Studies have shown that an average of 90-minutes of daily outdoor play time can help slow down the onset of myopia development.

Call 713-838-2020 or email [email protected] to schedule an appointment. Our experienced doctors will help you find the best treatment options to manage your child’s myopia progression.

FDA-Approved Myopia Management Treatments and Published Clinical Trials Results

Written by Dr. Bridgitte Shen Lee

Dr. Bridgitte Shen Lee earned her Doctor of Optometry degree magna cum laude from the University of Houston College of Optometry. She is the co-founder of Vision Optique® and founder of iTravelCE®. Dr. Shen Lee writes and lectures on the topics of Digital Eye Health® , Dry Eye Disease, Anti-Aging Eye Care, Health Care Social Media, and Ocular Aesthetics. She has presented lectures, seminars, and scientific posters globally at the World Council of Optometry, Optometric Management Symposium, SECO International, The Association for Research in Vision and Ophthalmology (ARVO), The British Contact Lens Association (BCLA), American Academy of Optometry, and Vision Expo.
instagram facebook facebook2 pinterest twitter google-plus google linkedin2 yelp youtube phone location calendar share2 link star-full star-half star star-half chevron-right chevron-left chevron-down chevron-up envelope fax